Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Hepatocellular 38 Carcinoma, Non-Small-Cell Lung 23 Stomach Neoplasms 19 Nasopharyngeal Carcinoma 19 Triple Negative Breast Neoplasms 18 Esophageal Squamous Cell Carcinoma 17 Esophageal Neoplasms 16 Breast Neoplasms 15 Squamous Cell Carcinoma of Head and Neck 13 Colorectal Neoplasms 11 Uterine Cervical Neoplasms 10 Pancreatic Neoplasms 8 Sarcoma 6 Recurrence 6 Neoplasm Metastasis 6 Melanoma 6 Liver Neoplasms 6 Cholangiocarcinoma 6 Lung Neoplasms 5 Hodgkin Disease 5 Biliary Tract Neoplasms 5 Osteosarcoma 4 Neoplasms 4 Locally Advanced Gastric Cancer 4 Advanced Gastric Cancer 4 Rectal Neoplasms 3 Nasopharyngeal Neoplasms 3 Glioblastoma 3 Gestational Trophoblastic Disease 3 Urinary Bladder Neoplasms 2

Interventions

Granulocyte-Macrophage Colony-Stimulating Factor 2 Colony-Stimulating Factors 2 nabiximols 1 fludarabine 1 camrelizumab 1 Radiofrequency Ablation 1 Interleukin-2 1 Immune Checkpoint Inhibitors 1 Cyclophosphamide 1 Adjuvants, Immunologic 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Advanced Malignant Solid Tumor × camrelizumab × Clear all

NCT03171220 2017-06-06

NRT-01

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Phase 1/2 Unknown

Other solid neoplasm

Advanced Malignant Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡